Biosimilar Antibodies

Mebarase alfa Biosimilar – Research Grade, ProteoGenix, PX-TA2496-100

Meplazumab Biosimilar – Anti-CD147 mAb – Research Grade, ProteoGenix, PX-TA1619

Description of Meplazumab Biosimilar - Anti-CD147 mAb - Research Grade Introduction Meplazumab Biosimilar, also known as Anti-CD147 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Meplazumab antibody. It targets the CD147 protein, which is overexpressed in various cancers and inflammatory diseases. Meplazumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential therapeutic option for these diseases. Structure of Meplazumab Biosimilar Meplazumab Biosimilar is a recombinant humanized monoclonal antibody that has been engineered to mimic the structure of the original Meplazumab antibody. It is composed of two heavy chains and two light chains, each consisting of variable and constant regions. The variable regions of the antibody are responsible for binding to the CD147 protein, while the constant regions determine the effector functions of the antibody. Activity of Meplazumab Biosimilar The primary activity of Meplazumab Biosimilar is to bind to the CD147 protein and inhibit its function. CD147 is a cell surface glycoprotein that plays a crucial role in cell adhesion, migration, and invasion. It is also involved in the regulation of immune responses and is overexpressed in various cancers and inflammatory diseases. By binding to CD147, Meplazumab Biosimilar blocks its interaction with other proteins and disrupts its function, leading to a decrease in cell proliferation and migration. In addition to its inhibitory activity, Meplazumab Biosimilar also has effector functions that can contribute to its therapeutic efficacy. These include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). ADCC involves the activation of immune cells, such as natural killer cells, to target and kill cancer cells that are bound by Meplazumab Biosimilar. CDC, on the other hand, involves the activation of the complement system, which leads to the destruction of target cells. Application of Meplazumab Biosimilar Meplazumab Biosimilar has shown promising results in preclinical studies as a potential therapeutic option for various cancers and inflammatory diseases. It has been evaluated in several in vitro and in vivo studies, which have demonstrated its ability to inhibit cell proliferation, migration, and invasion in cancer cells. In addition, Meplazumab Biosimilar has also shown anti-inflammatory effects in models of inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis. Currently, Meplazumab Biosimilar is being evaluated in clinical trials for the treatment of multiple myeloma, non-small cell lung cancer, and inflammatory bowel disease. These trials aim to assess the safety and efficacy of Meplazumab Biosimilar in patients and determine its potential as a therapeutic option for these diseases. Conclusion In summary, Meplazumab Biosimilar is a recombinant humanized monoclonal antibody that targets the CD147 protein, which is overexpressed in various cancers and inflammatory diseases. Its primary activity is to inhibit the function of CD147, and it also has effector functions that can contribute to its therapeutic efficacy. Meplazumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential therapeutic option for multiple myeloma, non-small cell lung cancer, and inflammatory bowel disease. Further research and clinical trials will determine the full potential of Meplazumab Biosimilar as a therapeutic antibody.

Merinetug Biosimilar – Research Grade, ProteoGenix, PX-TA2497-100

Metelimumab Biosimilar – Anti-TGFB1 mAb – Research Grade, ProteoGenix, PX-TA1138

Description of Metelimumab Biosimilar - Anti-TGFB1 mAb - Research Grade Introduction Metelimumab Biosimilar, also known as anti-TGFB1 mAb, is a research grade antibody that targets the protein transforming growth factor beta 1 (TGFB1). This antibody is being developed as a potential therapeutic option for various diseases and conditions related to TGFB1 dysregulation. In this article, we will explore the structure, activity, and potential applications of Metelimumab Biosimilar. Structure of Metelimumab Biosimilar Metelimumab Biosimilar is a monoclonal antibody, meaning it is produced from a single type of immune cell. It is a humanized antibody, which means it is derived from non-human sources but has been modified to be more similar to human antibodies. This allows for better compatibility and reduced risk of immune reactions in patients. The antibody is composed of two heavy chains and two light chains, which are connected by disulfide bonds. It has a molecular weight of approximately 150 kDa. Metelimumab Biosimilar specifically binds to the active form of TGFB1, preventing it from interacting with its receptors and exerting its effects. Activity of Metelimumab Biosimilar TGFB1 is a multifunctional cytokine that plays a crucial role in various physiological processes, including cell growth, differentiation, and immune response. However, dysregulation of TGFB1 has been linked to the development and progression of many diseases, including cancer, fibrosis, and autoimmune disorders. Metelimumab Biosimilar works by specifically binding to TGFB1 and inhibiting its activity. This prevents TGFB1 from promoting inflammation, fibrosis, and other pathological processes. By targeting the active form of TGFB1, Metelimumab Biosimilar has the potential to treat a wide range of diseases and conditions associated with TGFB1 dysregulation. Potential Applications of Metelimumab Biosimilar As mentioned earlier, Metelimumab Biosimilar has the potential to be used as a therapeutic option for various diseases and conditions related to TGFB1 dysregulation. Some of the potential applications of this antibody include: Cancer TGFB1 has been shown to promote tumor growth and metastasis in various types of cancer. By inhibiting TGFB1 activity, Metelimumab Biosimilar could potentially slow down tumor growth and prevent its spread to other parts of the body. This antibody could also be used in combination with other cancer treatments to enhance their effectiveness. Fibrosis Fibrosis is a condition characterized by the excessive accumulation of scar tissue in organs. TGFB1 is a major contributor to the development of fibrosis, and its inhibition by Metelimumab Biosimilar could potentially slow down or even reverse the progression of this condition. Autoimmune Disorders In autoimmune disorders, the immune system mistakenly attacks healthy tissues in the body. TGFB1 has been shown to play a role in the development and maintenance of autoimmune responses. By inhibiting TGFB1 activity, Metelimumab Biosimilar could potentially reduce the severity of autoimmune disorders and improve patient outcomes. Other Potential Applications Besides the above-mentioned conditions, Metelimumab Biosimilar could also have potential applications in other diseases and conditions, such as pulmonary fibrosis, diabetic nephropathy, and inflammatory bowel disease. Further research and clinical trials are needed to explore the full potential of this antibody. Conclusion In conclusion, Metelimumab Biosimilar is a research grade antibody that specifically targets the active form of TGFB1. By inhibiting TGFB1 activity, this antibody has the potential to treat a wide range of diseases and conditions related to TGFB1 dysregulation. With ongoing research and development, Metelimumab Biosimilar could potentially become a valuable therapeutic option for patients in the future.

Mezagitamab Biosimilar – Anti-CD38 mAb – Research Grade, ProteoGenix, PX-TA1543

Description of Mezagitamab Biosimilar - Anti-CD38 mAb - Research Grade Introduction Mezagitamab Biosimilar, also known as Anti-CD38 mAb, is a research grade monoclonal antibody that has been developed as a potential therapeutic agent for various diseases. This antibody specifically targets CD38, a cell surface protein that is involved in several biological processes, making it a promising therapeutic target. Structure of Mezagitamab Biosimilar Mezagitamab Biosimilar is a recombinant humanized monoclonal antibody that is produced using advanced biotechnology techniques. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa. Mechanism of Action Mezagitamab Biosimilar works by binding to CD38 on the surface of cells. CD38 is a transmembrane glycoprotein that is expressed on various cell types, including immune cells, plasma cells, and some cancer cells. When Mezagitamab Biosimilar binds to CD38, it triggers a series of events that ultimately lead to the destruction of the target cell. Activation of Immune Response One of the main mechanisms of action of Mezagitamab Biosimilar is the activation of the immune response. CD38 is involved in the regulation of immune cell function, and its overexpression has been linked to immune dysfunction in various diseases. By targeting and binding to CD38, Mezagitamab Biosimilar can modulate the activity of immune cells, leading to enhanced immune response against diseased cells. Induction of Apoptosis Mezagitamab Biosimilar also induces apoptosis, or programmed cell death, in cells that express high levels of CD38. This mechanism is particularly relevant in cancer cells, as they often evade apoptosis and continue to grow uncontrollably. By binding to CD38, Mezagitamab Biosimilar activates signaling pathways that promote apoptosis, effectively killing cancer cells. Applications of Mezagitamab Biosimilar Mezagitamab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases, including multiple myeloma, chronic lymphocytic leukemia, and autoimmune diseases. Multiple Myeloma Multiple myeloma is a type of blood cancer that affects plasma cells. CD38 is highly expressed on the surface of multiple myeloma cells, making it an ideal target for Mezagitamab Biosimilar. In preclinical studies, Mezagitamab Biosimilar has shown significant anti-tumor activity and prolonged survival in animal models of multiple myeloma. Chronic Lymphocytic Leukemia Chronic lymphocytic leukemia (CLL) is a type of cancer that affects white blood cells. CD38 is expressed at high levels on the surface of CLL cells, making it a potential therapeutic target. Mezagitamab Biosimilar has shown promising results in preclinical studies, with significant reduction in tumor burden and improved survival rates in animal models of CLL. Autoimmune Diseases CD38 is involved in the regulation of immune cell function, and its overexpression has been linked to autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Mezagitamab Biosimilar has shown potential in preclinical studies for the treatment of these diseases, by modulating the activity of immune cells and reducing inflammation. Conclusion Mezagitamab Biosimilar, also known as Anti-CD38 mAb, is a research grade monoclonal antibody that specifically targets CD38. Its unique mechanism of action, which involves activation of the immune response and induction of apoptosis, makes it a promising therapeutic agent for various diseases. With ongoing research and clinical trials, Mezagitamab Biosimilar has the potential to improve the treatment options for patients with multiple myeloma, chronic lymphocytic leukemia, and autoimmune diseases.

Milatuzumab Biosimilar – Anti-CD74 mAb – Research Grade, ProteoGenix, PX-TA1095

Description of Milatuzumab Biosimilar - Anti-CD74 mAb - Research Grade Milatuzumab Biosimilar – Anti-CD74 mAb – Research Grade Milatuzumab Biosimilar – Anti-CD74 mAb – Research Grade Introduction Milatuzumab Biosimilar is a monoclonal antibody (mAb) that targets the CD74 protein. It is a biosimilar version of the original Milatuzumab, which was developed and approved for clinical use in the treatment of B-cell malignancies. The biosimilar version has been designed to have the same structure, activity, and therapeutic potential as the original, but at a more affordable cost for research purposes. Structure Milatuzumab Biosimilar is a humanized IgG1 kappa monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a constant region (Fc) and a variable region (Fab), with the Fab region responsible for binding to the CD74 protein. Activity The main activity of Milatuzumab Biosimilar is its ability to bind to the CD74 protein. CD74 is a cell surface protein that is overexpressed in various types of cancer, including B-cell malignancies. By binding to CD74, Milatuzumab Biosimilar can block its activity and inhibit the growth and survival of cancer cells. It can also trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further enhance its anti- cancer effects. Application Milatuzumab Biosimilar has a wide range of potential applications in cancer research. It can be used as a tool for studying the role of CD74 in cancer development and progression. It can also be used to screen for potential therapeutic targets and to evaluate the efficacy of novel anti- cancer drugs. Additionally, Milatuzumab Biosimilar can be used in pre-clinical studies to assess its potential as a therapeutic agent for B-cell malignancies and other CD74-expressing cancers. Therapeutic Target The main therapeutic target of Milatuzumab Biosimilar is the CD74 protein. CD74 is a transmembrane protein that is involved in various cellular processes, including immune response, cell proliferation, and survival. It is overexpressed in many types of cancer and has been identified as a potential therapeutic target for cancer treatment. By targeting CD74, Milatuzumab Biosimilar can disrupt the signaling pathways that promote cancer cell growth and survival, leading to tumor regression and improved patient outcomes. Conclusion Milatuzumab Biosimilar is a promising research tool for studying the role of CD74 in cancer and evaluating its potential as a therapeutic target. Its similar structure and activity to the original Milatuzumab make it a cost-effective option for pre-clinical studies. With its ability to inhibit cancer cell growth and trigger immune-mediated cytotoxicity, Milatuzumab Biosimilar has the potential to be a valuable addition to the arsenal of anti- cancer therapies.

Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade, ProteoGenix, PX-TA1489

Description of Mirikizumab Biosimilar - Anti-IL23A mAb - Research Grade Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade: A Promising Antibody for Targeting IL-23A Introduction Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade is a novel antibody that has been developed as a biosimilar of the well-known monoclonal antibody, mirikizumab. This biosimilar is specifically designed to target and inhibit the activity of interleukin-23A (IL-23A), a cytokine that plays a crucial role in the pathogenesis of various inflammatory and autoimmune diseases. In this article, we will provide a comprehensive scientific description of the structure, activity, and potential applications of Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade. Structure of Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade is a monoclonal antibody that is produced by recombinant DNA technology. It is a fully humanized antibody, meaning that it is derived from human cells and has a structure that closely resembles natural human antibodies. The antibody consists of two identical heavy chains and two identical light chains, each containing variable and constant regions. The variable regions are responsible for binding to the target molecule, IL-23A, while the constant regions determine the effector functions of the antibody. Mechanism of Action Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade works by binding to IL-23A and preventing it from interacting with its receptor, IL-23R. This inhibits the downstream signaling pathways that lead to the production of pro-inflammatory cytokines, such as IL-17 and IL-22. By blocking IL-23A, the antibody effectively reduces the inflammation and tissue damage associated with various diseases, including psoriasis, psoriatic arthritis, and Crohn’s disease. Potential Applications As a biosimilar of mirikizumab, Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade has the potential to be used in the treatment of various inflammatory and autoimmune diseases. It has shown promising results in clinical trials for psoriasis, psoriatic arthritis, and Crohn’s disease, and is currently being evaluated for other conditions, such as ulcerative colitis and ankylosing spondylitis. In addition, the biosimilar form of mirikizumab offers a more affordable treatment option for patients, making it accessible to a larger population. Advantages of Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade Compared to other anti-IL23A therapies, Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade has several advantages. Firstly, being a biosimilar, it has a similar safety and efficacy profile as the original mirikizumab, making it a reliable treatment option. Secondly, its fully humanized structure reduces the risk of immunogenicity, which is a common issue with other monoclonal antibodies. Lastly, the biosimilar form of mirikizumab is more cost-effective, making it a more accessible option for patients. Conclusion Mirikizumab Biosimilar – Anti-IL23A mAb – Research Grade is a promising antibody that has the potential to revolutionize the treatment of inflammatory and autoimmune diseases. Its unique structure, mechanism of

Miromavimab Biosimilar – Anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-II mAb – Research Grade, ProteoGenix, PX-TA1687

Description of Miromavimab Biosimilar - Anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-II mAb - Research Grade Introduction Miromavimab Biosimilar, also known as Anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-II mAb – Research Grade, is a monoclonal antibody (mAb) that specifically targets the glycoprotein (GP) of the rabies virus strain ERA. This biosimilar is a promising therapeutic option for the treatment of rabies, a deadly viral disease that affects millions of people worldwide. Structure Miromavimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each consisting of variable and constant regions. The variable regions of the heavy and light chains are responsible for binding to the GP of the rabies virus strain ERA. Activity Miromavimab Biosimilar exerts its activity by binding to the GP of the rabies virus strain ERA and preventing its interaction with host cell receptors. This inhibits the virus from entering and infecting cells, effectively neutralizing its ability to cause disease. Additionally, the binding of the antibody to the GP can also trigger the immune system to mount a response against the virus, further enhancing its efficacy. Application Miromavimab Biosimilar has shown promising results in pre-clinical studies and is currently being evaluated in clinical trials for its potential as a treatment for rabies. It is being developed as a research-grade antibody, which means that it is intended for use in laboratory research and not for human therapeutic purposes. However, the results from these studies can provide valuable insights for the development of a potential therapeutic antibody for rabies in the future. Potential as a Therapeutic Antibody The development of Miromavimab Biosimilar as a therapeutic antibody for rabies has the potential to revolutionize the treatment of this deadly disease. Currently, the standard treatment for rabies is the administration of rabies immunoglobulin (RIG) along with a series of rabies vaccines. However, RIG is derived from human or animal blood, which poses a risk of contamination and limited availability in some regions. In contrast, Miromavimab Biosimilar is a recombinant antibody, which can be produced in large quantities in a controlled environment, ensuring its safety and availability. Furthermore, Miromavimab Biosimilar has the potential to be used as a post-exposure prophylaxis for rabies. This means that it can be administered to individuals who have been exposed to the rabies virus, but have not yet developed symptoms. This can prevent the virus from causing infection and potentially save lives. Conclusion In conclusion, Miromavimab Biosimilar is a promising monoclonal antibody that specifically targets the glycoprotein of the rabies virus strain ERA. Its unique structure and mechanism of action make it a potential therapeutic option for the treatment of rabies. Further research and clinical trials are needed to fully evaluate its efficacy and safety, but it holds great potential in revolutionizing the treatment of this deadly disease.

Mirvetuximab Biosimilar – Anti-FOLR1 mAb – Research Grade, ProteoGenix, PX-TA1412

Description of Mirvetuximab Biosimilar - Anti-FOLR1 mAb - Research Grade General information on Anti-FOLR1[Homo sapiens] (Mirvetuximab) Monoclonal Antibody Mirvetuximab is monoclonal antibody that targets folate receptor alpha (FR alpha). It has been used in ADC form to treat cancers.

Mirzotamab Biosimilar – Anti-CD276, B7-H3 mAb – Research Grade, ProteoGenix, PX-TA1596

Description of Mirzotamab Biosimilar - Anti-CD276, B7-H3 mAb - Research Grade Title: Mirzotamab Biosimilar – A Promising Antibody for Targeting B7-H3 in Cancer Therapy Introduction: Mirzotamab Biosimilar, also known as Anti-CD276 or B7-H3 mAb, is a novel monoclonal antibody that has shown promising results in cancer therapy. This biosimilar is designed to target B7-H3, a protein that is overexpressed in various types of cancer, making it an attractive therapeutic target. In this article, we will discuss the structure, mechanism of action, and potential applications of Mirzotamab Biosimilar in cancer treatment. Structure of Mirzotamab Biosimilar: Mirzotamab Biosimilar is a fully human monoclonal antibody with a molecular weight of approximately 150 kDa. It consists of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chain contains a constant region (Fc) and a variable region (Fab), while the light chain has only a variable region. The variable regions of both the heavy and light chains are responsible for binding to the target protein, B7-H3. Mechanism of Action: B7-H3 is a cell surface protein that is overexpressed in various types of cancer, including lung, breast, and prostate cancer. It plays a crucial role in tumor growth and progression by promoting angiogenesis, suppressing immune response, and enhancing tumor cell survival. Mirzotamab Biosimilar works by binding to B7-H3 and blocking its activity, thus inhibiting tumor growth and promoting immune response against cancer cells. Applications of Mirzotamab Biosimilar: 1. Targeted Therapy for Cancer: Mirzotamab Biosimilar has shown promising results in preclinical studies as a targeted therapy for various types of cancer. In a study conducted on lung cancer cell lines, Mirzotamab Biosimilar was found to significantly inhibit tumor growth and induce cell death. Similarly, in a study on breast cancer, this biosimilar showed a significant reduction in tumor size and improved survival rates. These results indicate the potential of Mirzotamab Biosimilar as a targeted therapy for cancer. 2. Combination Therapy: Mirzotamab Biosimilar has also shown potential as a combination therapy in cancer treatment. In a study on prostate cancer, it was found that the combination of Mirzotamab Biosimilar and another targeted therapy resulted in a more significant reduction in tumor growth compared to either therapy alone. This suggests that Mirzotamab Biosimilar can be used in combination with other therapies to enhance their efficacy. 3. Immunotherapy: B7-H3 is known to suppress immune response against cancer cells, making them resistant to conventional therapies. By blocking the activity of B7-H3, Mirzotamab Biosimilar can restore immune response and sensitize cancer cells to other treatments. This makes it a potential candidate for immunotherapy in cancer treatment. 4. Research Grade Antibody: Apart from its therapeutic applications, Mirzotamab Biosimilar can also be used as a research grade antibody for studying the role of B7-H3 in cancer. Its high specificity and affinity for B7-H3 make it a valuable tool for investigating the function of this protein in different types of cancer. Conclusion: Mirzotamab Biosimilar is a promising antibody for targeting B7-H3 in cancer therapy. Its unique structure, mechanism of action, and potential applications make it a valuable addition to the arsenal of cancer treatments. Further clinical studies are needed to establish its safety and efficacy in humans, but the preclinical data is highly promising. With its potential to improve cancer treatment outcomes, Mirzotamab Biosimilar has the potential to make a significant impact in the field of oncology.